Image analysis and tumor biomarker specialist Definiens is being bought AstraZeneca as it consolidates its position in oncology R&D. AstraZeneca's MedImmune unit will acquire 100% of Definiens' shares for $150m upfront and make additional predetermined milestone payments.
Definiens has developed a world-leading imaging and data analysis technology, known as Tissue Phenomics, which dramatically improves the identification of...





